鲁索替尼乳膏（Opzelura）可以有效治疗特应性皮炎

It is a Janus kinase (JAK) inhibitor that selectively inhibits JAK1/JAK2. JAKs belong to a family of cytoplasmic tyrosine kinases whose function is to mediate the signal transduction of many cytokines (such as interferons) that are important for hematopoietic and immune functions.

The U.S. Food and Drug Administration (FDA) has approved ruxolitinib cream (Opzelura) for the short-term and discontinuous long-term treatment of patients 12 years and older with mild to moderate atopic dermatitis (AD). This drug is the first and only topical preparation of a JAK inhibitor approved by the US FDA.

The results of two randomized, double-blind, vehicle-controlled phase 3 clinical trials showed that compared with vehicle, the proportion of patients who received ruxolitinib cream (Opzelura) at different doses after 8 weeks of treatment was significantly better than the control group. The clinical trial results show that ruxolitinib cream (Opzelura) has a significant effect in treating atopic dermatitis, can improve the patient's quality of life, and has a positive effect on the patient's condition.

The recommended dose of ruxolitinib cream (Opzelura) is to apply a thin layer of the product to no more than 20% of the affected area of the body twice daily. The weekly dosage should not exceed 60g. Ruxolitinib cream (Opzelura) is for topical use only and not for ophthalmic, oral, or intravaginal use.

Use of ruxolitinib cream (Opzelura) should be discontinued when the signs and symptoms of atopic dermatitis subside. If the signs and symptoms do not improve within 8 weeks of treatment with the drug, the patient's physical condition will need to be re-examined by the healthcare provider. When patients receive ruxolitinib cream (Opzelura) and follow the correct usage method, they believe they will have good results soon.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: